Correlation Between Inhibikase Therapeutics and Seres Therapeutics

Can any of the company-specific risk be diversified away by investing in both Inhibikase Therapeutics and Seres Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibikase Therapeutics and Seres Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Inhibikase Therapeutics and Seres Therapeutics, you can compare the effects of market volatilities on Inhibikase Therapeutics and Seres Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibikase Therapeutics with a short position of Seres Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibikase Therapeutics and Seres Therapeutics.

Diversification Opportunities for Inhibikase Therapeutics and Seres Therapeutics

0.42

Correlation Coefficient

Inhibikase Therapeutics  Seres Therapeutics

Very weak diversification

The 3 months correlation between Inhibikase and Seres is 0.42. Overlapping area represents the amount of risk that can be diversified away by holding Inhibikase Therapeutics and Seres Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Seres Therapeutics and Inhibikase Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibikase Therapeutics are associated (or correlated) with Seres Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Seres Therapeutics has no effect on the direction of Inhibikase Therapeutics i.e., Inhibikase Therapeutics and Seres Therapeutics go up and down completely randomly.

Pair Corralation between Inhibikase Therapeutics and Seres Therapeutics

Considering the 90-day investment horizon Inhibikase Therapeutics is expected to generate 1.27 times more return on investment than Seres Therapeutics. However, Inhibikase Therapeutics is 1.27 times more volatile than Seres Therapeutics. It trades about 0.23 of its potential returns per unit of risk. Seres Therapeutics is currently generating about 0.06 per unit of risk. If you would invest  130.00  in Inhibikase Therapeutics on October 10, 2024 and sell it today you would earn a total of  191.00  from holding Inhibikase Therapeutics or generate 146.92% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Inhibikase Therapeutics  vs.  Seres Therapeutics

Inhibikase Therapeutics

Risk-Adjusted Performance

18 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Inhibikase Therapeutics are ranked lower than 18 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady forward-looking signals, Inhibikase Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Seres Therapeutics

Risk-Adjusted Performance

4 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Seres Therapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain basic indicators, Seres Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Inhibikase Therapeutics and Seres Therapeutics

The main advantage of trading using opposite Inhibikase Therapeutics and Seres Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibikase Therapeutics position performs unexpectedly, Seres Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Seres Therapeutics will offset losses from the drop in Seres Therapeutics' long position.

The idea behind Inhibikase Therapeutics and Seres Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.